US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Edgewise Therapeutics
< Previous
1
2
Next >
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
March 11, 2025
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025
March 04, 2025
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
January 22, 2025
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
January 13, 2025
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
January 07, 2025
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
December 16, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research
December 05, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
November 26, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 07, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
October 01, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
September 19, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
September 17, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
May 10, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
May 07, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
May 06, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
April 23, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
April 15, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
March 28, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
March 27, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
March 05, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
February 28, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
February 22, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
February 13, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
January 19, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
January 09, 2024
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
December 19, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community
December 18, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
November 30, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
< Previous
1
2
Next >
